







- 
- 
- Patient: woman 32 y. old
  - Abdominal pain, peripheral nodes 2 cm (cervical, axillar and inguinal)
  - CT scan: huge abdominal mass
  - LDH: X 2N
  - Cervical biopsy: Follicular lymphoma grade 2
  - FLIPI = 3
  - SUV max: 25 (mesenteric lymph node)

# Pet scan




# PET-CT

**SUV max: 25**




# Treatment

- R-CHOP 21
- 4 cycles before CT scan (not PET scan) evaluation
  - Unconfirmed CR (80% reduction)
- 2 additional cycles of R-CHOP+ 2 infusions of rituximab (according to PRIMA protocol)
  - PET-CT : persistence of an hyper metabolic lesion (lymph node 2cm retro oesophagus (SUV max = 6.2))
- Decision: “watch and wait”





at the end of treatment



## ... 6 months later




- Relapse : B symptoms, cervical lymphadenopathy (< 2cm), abdominal pain, anemia, LDH:X3N, hyperuricemia
- PET-CT :
  - Mesenteric mass (SUV max = 30)
  - In other areas: SUV between 3-5
- CT guided biopsy of the mesenteric mass: DLBCL



**SUV max: 30**





# Outcome

- **Salvage treatments**
  - RICE : 2 cycles... Failure
  - R-DHAOx: 4 cycles...transient response, then progression
- **Death occurred 8 months after relapse**



## Questions



- Is a CT-guided biopsy of the mesenteric mass indicated at baseline?
- Should PET scan be performed before first line treatment in order to decide a guided biopsy (second biopsy), in case of suspicion of more aggressive disease (B symptoms, elevated LDH level or FLIPI  $\geq 3$ , SUV > 10-15??)